

Subject:	Research and Development Quarterly Performance Report - Q1 2021/22		Date: 1st July 2021	
Prepared By:	Alison Steel, Head of Research and Innovation			
Approved By:	Elizabeth Gemmill, Research and Innovation Director			
Presented By:	Alison Steel			
Purpose				
To present the Research and Innovation Quarterly Performance Report			Decision	
Update and assurance on performance KPI's and financial position			Approval	
Update on recovery and growth of the SFH research portfolio			Assurance	X
Strategic Objectives				
To provide outstanding care	To promote and support health and wellbeing	To maximise the potential of our workforce	To continuously learn and improve	To achieve better value
X		X	X	X
Overall Level of Assurance				
	Significant	Sufficient	Limited	None
		X		
Risks/Issues				
Financial	<ul style="list-style-type: none"> Confirmed £752,652.04 EMCRN 2021/22 budget, plus additional £76,641.00 allocated post budget confirmation £26,779.50 successful CRN bid – Cancer services research Commercial income for re-investment £43,941.80 in Q1 2021/22 			
Patient Impact	<ul style="list-style-type: none"> 125 participants recruited in to research studies, 78 in to UPH studies 			
Staff Impact	<ul style="list-style-type: none"> COVID-19 research for staff participation secured for a further year Research Academy placements in place Collaboration with Nottingham Trent University to support development of clinical academic careers and research exposure for clinical staff 			
Services	<ul style="list-style-type: none"> Support Clinical Divisions with research engagement 			
Reputational	<ul style="list-style-type: none"> Retain a strong reputation for research delivery enhanced by the breadth of UPH delivered at SFH Exemplar in financial probity 			
Committees/groups where this item has been presented before				
None				
Executive Summary				
Performance Metrics				
<ul style="list-style-type: none"> 125 participants recruited in to research studies compared to 1071 Q1 20/21, 51 studies on the SFH portfolio Confirmed £752,652.04 EMCRN 2021/22 budget, plus additional £76,641.00 allocated post budget confirmation Commercial income at £43,941.80 				
Restart, Recovery and Growth				
<ul style="list-style-type: none"> 58 trials suspended during pandemic, 54 studies reopened, 3 now closed, 22 new studies in set up Focus on recovering commercial trials Targeted approach for developing research opportunities in cancer services Research Academy placements 				

COVID-19 research studies taking place at SFH

- 10 studies have been active throughout Q1

Research Priorities

1. Restart and recover the SFH research portfolio with a specific focus on commercial research
2. Work with and support Clinical Divisions with research engagement
3. Further develop partnership with Nottingham Trent University to support development of clinical academic careers and research skills for clinical staff relevant to their role; including training, mentoring and research idea development
4. Work closely with the transformation team to develop a mechanism to capture and cultivate innovation with a focus on commercialisation and intellectual property
5. Develop an R&I plan across the system - SFH representation on the ICS R&I Executive Group as key contributors to the planning and coordination of services, ensuring equal access to research across the region.
6. Broadening collaboration with primary care and NUH partners to make participation in research easier for our communities
7. Creating a research environment at SFH which can deliver digitally enabled trials